TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341

Benzinga Newsdesk www.benzinga.com Positive 87.1%

Neg 0% Neu 0% Pos 87.1%

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.